loading...| Preferred Name |
meloxicam |
|
| Synonyms |
Movatec |
|
| Definitions |
An oxicam derivative and a non-steroidal anti-inflammatory drug (NSAID) with anti-inflammatory, antipyretic and analgesic activities. Unlike traditional nonselective NSAIDs, meloxicam preferentially inhibits the activity of cyclo-oxygenase II (COX-II), resulting in a decreased conversion of arachidonic acid into prostaglandin precursors. The resulting decrease in prostaglandin synthesis is responsible for the therapeutic effects of meloxicam. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C61439" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C61439" NCI Thesaurus) |
|
| ID |
http://purl.bioontology.org/ontology/PDQ/CDR0000472195 |
|
| altLabel |
Movatec Mobicox Movalis Mobic 4-Hydroxy-2-methyl-N-(5-methyl-2-thiazolyl)-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide Mobec |
|
| CAS Registry |
71125-38-7 |
|
| cui |
C1831767 C0083381 C0592680 C0642799 |
|
| DATE FIRST PUBLISHED |
2006-03-10 |
|
| Date last modified |
2006-10-10 |
|
| definition |
An oxicam derivative and a non-steroidal anti-inflammatory drug (NSAID) with anti-inflammatory, antipyretic and analgesic activities. Unlike traditional nonselective NSAIDs, meloxicam preferentially inhibits the activity of cyclo-oxygenase II (COX-II), resulting in a decreased conversion of arachidonic acid into prostaglandin precursors. The resulting decrease in prostaglandin synthesis is responsible for the therapeutic effects of meloxicam. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C61439" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C61439" NCI Thesaurus) |
|
| LT |
TRD |
|
| NCI ID |
C61439 |
|
| notation |
CDR0000472195 |
|
| ORIG STY |
Drug/agent |
|
| prefLabel |
meloxicam |
|
| tui |
T109 T121 |